The QualityStocks Daily Wednesday, September 20th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(FRTX) $0.8960 +53.71%

Schaeffer's(SCS) $10.5100 +19.30%

Tiny Gems(RENB) $3.3900 +14.92%

The QualityStocks Daily Stock List

Fresh Tracks Therapeutics (FRTX)

QualityStocks, MarketClub Analysis, 360wallstreet and 247 Market News reported earlier on Fresh Tracks Therapeutics (FRTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fresh Tracks Therapeutics Inc. (NASDAQ: FRTX) (FRA: VCC) is a clinical-stage pharmaceutical firm that is focused on developing a range of prescription therapeutics for the treatment of inflammatory, autoimmune and other debilitating illnesses.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2009 by Andrew D. Sklawer and Reginald L. Hardy. Prior to its name change in September 2022, the firm was known as Brickell Biotech Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the world, with a focus on those in the United States.

The company’s primary focus is to transform the lives of patients by developing ground-breaking and innovative prescription therapeutics. It is party to license and collaboration agreements with AnGes Inc., Dr. Nicholas S. Bodor, Bodor Laboratories Inc., Voronoi Inc. and Carna Biosciences Inc.

The enterprise’s product pipeline is comprised of a covalent stimulator of interferon genes inhibitor known as BBI-10, for the potential treatment of rare genetic and auto-inflammatory illnesses; an oral DYRK1A inhibitor dubbed BBI-02for the treatment of inflammatory and autoimmune illnesses; and sofpironium bromide, which has completed Phase 3 trials evaluating its effectiveness in treating primary auxiliary hyperhidrosis.

The firm, which recently rebranded and established a scientific advisory board, remains focused on its mission to develop new therapies that restore immune balance. The success and approval of its therapies will not only benefit patients with a range of indications but also significantly bolster its overall growth.

Fresh Tracks Therapeutics (FRTX), closed Wednesday's trading session at $0.896, up 53.7142%, on 11,008,133 volume. The average volume for the last 3 months is 138,801 and the stock's 52-week low/high is $0.4495/$3.14.

The Hong Kong & China Gas (HOKCY)

DividendStocks, StreetInsider and MarketBeat reported earlier on The Hong Kong & China Gas (HOKCY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Hong Kong & China Gas Company Ltd (OTC: HOKCY) (HKG: 0003) (FRA: HCG) is a public utility firm engaged in the production, distribution and marketing of gas, water supply and energy services.

The firm has its headquarters in North Point, Hong Kong and was incorporated in 1862. It operates as part of the utilities-regulated gas industry, under the utilities sector. The firm primarily serves consumers in Hong Kong and Mainland China.

The enterprise operates through the Gas, Water & Related Business; New Energy; Property; and Others segments. It is involved in water supply and wastewater treatment; smart energy, piped city-gas, upstream and midstream projects; urban waste resource utilization, and natural gas filling stations, as well as new energy exploration and utilization activities. The enterprise develops new energy projects that are low in emissions and pollution, which includes clean coal chemical business, liquefaction of methane, etc., as well as supplies town gas. It also offers network connectivity, data center, and ICT services, as well as engineering, procurement, and construction services. In addition to this, the enterprise designs and manufactures gas meters and metering systems as well as provides consultancy and engineering contractor services, including utilities installation, infrastructure construction, and civil and building services engineering for public and private projects. Furthermore, it is engaged in software development, solution implementation, and systems integration activities as well as the manufacture of polyethylene piping and fittings.

The company, which recently diversified its business into telecommunications, building services, engineering and new eco-energies among many other fields, remains committed to expanding its business horizons which may positively influence investments into the company and its overall growth.

The Hong Kong & China Gas (HOKCY), closed Wednesday's trading session at $0.6698, up 0.84312%, on 18,860 volume. The average volume for the last 3 months is 334,784 and the stock's 52-week low/high is $0.6448/$1.01.

Amprius Technologies (AMPX)

Schaeffer's, QualityStocks, MarketBeat and FreeRealTime reported earlier on Amprius Technologies (AMPX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Amprius Technologies Inc. (NYSE: AMPX) (NYSE: AMPX+) is a company focused on the production and sale of ultra-high energy density and high-capacity lithium-ion batteries for mobility applications.

The firm has its headquarters in Fremont, California and was incorporated in 2008 by Mark C. Platshon. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm mainly serves consumers in the United States.

The company maintains an R&D lab and a pilot manufacturing facility for the fabrication of silicon nanowire anodes and cells. It leverages disruptive silicon anodes to produce its high energy density lithium-ion battery for mobility applications. Its technology has the potential for application in electric transportation.

The enterprise’s silicon anode technology enables batteries with higher energy density, higher power density, and fast charging capabilities over a range of operating temperatures. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing process leverages the manufacturing process for conventional lithium-ion batteries and the related supply chain. The enterprise’s batteries are primarily used for existing and emerging aviation applications, including unmanned aerial systems (UAS), such as drones and high-altitude pseudo satellites (HAPS).

The firm, which recently released its latest financial results, has unveiled a revolutionary battery pack in partnership with Tenergy. This move will not only allow the firm to better meet its consumer needs and address the demands of the UAS market but also open it up to new growth and investment opportunities. This may in turn help generate value for its shareholders.

Amprius Technologies (AMPX), closed Wednesday's trading session at $4.3, off by 0.232019%, on 474,945 volume. The average volume for the last 3 months is 4,951 and the stock's 52-week low/high is $3.281/$15.39.

CGN Mining (CGNMF)

InvestorPlace reported earlier on CGN Mining (CGNMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CGN Mining Company Ltd. (OTC: CGNMF) (HKG: 1164) (FRA: V8O) is an investment holding company focused on developing and trading natural uranium resources to nuclear power plants.

The firm has its headquarters in Wan Chai, Hong Kong and was incorporated in 1996. It operates as part of the uranium industry, under the energy sector. The firm mainly serves consumers in Hong Kong.

The company operates as a subsidiary of China Uranium Development Co. Ltd. It operates through the Natural Uranium Trading, Property Investment and Other Investments segments. The Natural Uranium Trading segment is involved in the trade of natural uranium. On the other hand, the Property Investment segment is focused on leasing and selling office premises while the Other Investments segment includes investment in a joint venture. The company generates the majority of its revenue from the trade of natural uranium. It has operations in the People's Republic of China, Canada, the United States, the United Kingdom and the rest of Europe.

The enterprise holds 49% equity interests in Semizbay-U Limited Liability Partnership and sales rights of the off-take quantity of products and 19.99% equity interests in Fission Uranium Corp. which is a Canadian uranium exploration company.

The firm remains focused on advancing its exploration efforts for uranium, exploring potential investment projects, growing in size and business scale and becoming a major player in the uranium industry. This may in turn open it up to new growth and investments opportunities as well as help create value for its shareholders.

CGN Mining (CGNMF), closed Wednesday's trading session at $0.15, even for the day. The average volume for the last 3 months is 8,461 and the stock's 52-week low/high is $0.0979/$0.16.

City Developments (CDEVY)

MarketBeat, Trades Of The Day, Daily Trade Alert and Zacks reported earlier on City Developments (CDEVY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

City Developments Limited (OTC: CDEVY) (SGX: C09) is a leading global real estate firm engaged in the provision of real estate services.

The firm has its headquarters in Singapore and was incorporated in 1963, on September 7th. It operates as part of the real estate-development industry, under the real estate sector. The firm serves consumers around the globe.

The company operates through the Property Development, Investment Properties, Hotel Operations and Others segments. The Property Development segment is focused on the development and purchase of properties for sale while the Investment Properties segment is involved in the development and purchase of investment properties for sale. On the other hand, the Hotel Operations segment owns and manages hotels while the Others segment includes investment in shares, provision of laundry services and management and consultancy services.

The enterprise’s network spans roughly 143 locations in 28 countries and regions. Its portfolio comprises of offices, residences, hotels, student accommodation, serviced apartments, retail malls and integrated developments. It has developed over 50,000 homes and owns around 21mft2 of gross floor area in residential for lease, commercial and hospitality assets globally. The enterprise also has more than 150 hotels in different parts of the world. Its diversified global land bank offers 3.5 million ft2 of land area.

The company, which has a proven track record of over 55 years in real estate development, investment and management, remains committed to expanding its portfolio and generating value for its shareholders.

City Developments (CDEVY), closed Wednesday's trading session at $4.84, off by 0.819672%, on 7,488 volume. The average volume for the last 3 months is 146,800 and the stock's 52-week low/high is $4.69/$6.51.

Waldencast (WALD) and MarketBeat reported earlier on Waldencast (WALD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Waldencast PLC (NASDAQ: WALD) (NASDAQ: WALDW) is a multi-brand beauty and wellness platform that is involved in the development, marketing and sale of skin health products.

The firm has its headquarters in White Plains, New York and was incorporated in 2020, on December 8th by Hind Sebti and Michel Brousset. It operates as part of the software-application industry, under the technology sector. The firm serves consumers from around the world.

The company is focused on developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It intends to seek brands with a direct connection to consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. The company’s subsidiaries include Obagi Global Holdings Limited and Milk Makeup LLC.

The enterprise provides about 200 cosmetic, over-the-counter, and prescription products under the Obagi Professional, Obagi Medical and Obagi Clinical brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. Obagi Skincare products are designed to diminish the appearance of photodamage, premature aging, skin discoloration, acne and sun damage. It sells its products to plastic surgeons, dermatologists and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force; and through distribution partners.

The firm, which recently took part in the Canaccord Genuity 43rd Annual Growth Conference, remains committed to realizing its vision of building a global best-in-class beauty and wellness platform and creating additional value for its shareholders.

Waldencast (WALD), closed Wednesday's trading session at $10.2, off by 3.5917%, on 286,998 volume. The average volume for the last 3 months is 4.748M and the stock's 52-week low/high is $5.0005/$12.10.

TJX Companies Inc. (TJX)

The Street, InvestorPlace, MarketClub Analysis, Schaeffer's, StocksEarning, Zacks, Kiplinger Today, MarketBeat, Daily Trade Alert, Market Intelligence Center Alert, StreetInsider, Top Pros' Top Picks, Louis Navellier, The Online Investor, Trades Of The Day, TheStockAdvisor, Market Report, TheStockAdvisors, WStreet Market Commentary, Daily Markets, Early Bird, Wealth Insider Alert, GorillaTrades, StockEarnings, Investopedia,, Barchart, DividendStocks, Daily Wealth, Daily Profit, InvestorsObserver Team, The Tycoon Report, The Wealth Report, Uncommon Wisdom, Trading Concepts, MarketWatch, Wyatt Investment Research, SmarTrend Newsletters, Market Intelligence Center, Profit Confidential, Money and Markets, Investors Alley, TopStockAnalysts, ChartAdvisor, Wall Street Greek, Money Morning, The Street Report, TradingMarkets, Trading Tips, TradersPro, TipRanks, StreetAlerts, The Stock Enthusiast, Investing Daily, InvestmentHouse, StreetAuthority Daily, Energy and Capital, Forbes, Coattail Investor, CNBC Breaking News, Dynamic Wealth Report, Stock Tips Network, The Growth Stock Wire, The Stock Dork, Street Insider, Wall Street Daily, Stockhouse, Wealth Week, SmallCap Network, Short Term Wealth, ProfitableTrading, Oakshire News Bulletin, Todd Horwitz, Darwin Investing Network, TheTradingReport, Trade of the Week, Trading For Keeps, Eagle Financial Publications, Dividend Opportunities, Trading Markets, Wealth Daily, The Wall Street Transcript, BUYINS.NET, Bloomfield Investment Club, YOLOTraderAlerts, Average Joe Options, AllPennyStocks, All about trends, Weekly Wizards, Investiv, Navellier Growth, 24/7 Trader, Smart Investing Society, Stealth Stocks, StockTwits, Investor Update, SureMoney, SystemTrading, The Stock Scout, Investment House, Early to Rise, Insider Wealth Alert, The Motley Fool, Greenbackers, Money Wealth Matters, FreeRealTime, Shah's Insights & Indictments, FeedTheBull, The Trading Report and Investment U reported earlier on TJX Companies Inc. (TJX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TJX (NYSE: TJX) was featured in a recent analysis report that discussed the retail giant’s secret to success. TJX, a modern-day merchant leading the off-price retail market, offers a shopping experience filled with discovery, excitement and...

To read the full report and view the infographic, please visit

About TJX Companies Inc.

TJX is the leading off-price retailer of apparel and home fashions in the U.S. and worldwide. As of July 29, 2023, the end of the company’s second quarter, the company operated a total of 4,884 stores in nine countries, the United States, Canada, the United Kingdom, Ireland, Germany, Poland, Austria, the Netherlands, and Australia, and seven e-commerce sites. For details regarding TJX’s press releases and financial information, visit

TJX Companies Inc. (TJX), closed Wednesday's trading session at $90.66, off by 0.373626%, on 5,078,455 volume. The average volume for the last 3 months is 856,307 and the stock's 52-week low/high is $59.78/$93.78.

Cresco Labs Inc. (CRLBF)

InvestorPlace, Kiplinger Today, Daily Trade Alert, MarketBeat, QualityStocks, Top Pros' Top Picks, The Street, Cabot Wealth, The Wealth Report, The Online Investor, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, Early Bird, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The United States is on the brink of a groundbreaking shift in its approach to marijuana policy. However, a significant obstacle stands in the way of this reform: the Drug Enforcement Administration (DEA).

Recognizing marijuana’s medical value, the U.S. Department of Health and Human Services ( HHS) recommended reclassifying marijuana as a Schedule III controlled substance in response to President Joe Biden’s call for a comprehensive review of marijuana scheduling last year. This pivotal moment in federal government policy places the key marijuana decision in the hands of the DEA, an agency historically associated with the country’s war on drugs.

The timeline for the DEA’s response remains uncertain, but experts speculate that an initial proposed rule could emerge by the year’s end, with finalization expected in the following spring. While the DEA cannot outright reject the HHS recommendation, its evaluation must encompass both legal and policy considerations, aligning with U.S. obligations under international drug-control treaties.

Barring an unlikely rejection of the HHS recommendation, the DEA must propose a federal law change consistent with the comprehensive scientific evaluation of marijuana. However, once the DEA suggests the change, more hurdles await, including a public comment period lasting typically 30 to 60 days, the DEA’s review of comments and potential lawsuits that could further delay implementation.

This marks the first time a president has ordered the DEA to review marijuana law, a significant departure from previous rejections of rescheduling petitions. The journey of marijuana through Capitol Hill bureaucracy began on Oct. 6, 2022, when President Biden instructed Cabinet-level agencies to expedite the review of marijuana scheduling.

Since 1970, marijuana has been classified as a Schedule I substance, defined as having no medicinal value and high potential for abuse. This designation poses significant challenges to legal marijuana businesses, including limited tax deductions, restricted access to mainstream banks and U.S.-based stock exchanges, and the constant threat of DEA raids. The federal ban also hampers research, product development, workplace safety regulations and health insurance matters. Previous efforts to challenge marijuana’s classification came through petitions or court actions by state governors and advocacy groups, such as NORML.

The DEA faces the challenge of creating a meticulous administrative record for impending lawsuits. Those lawsuits could potentially be filed by a wide range of individuals and organizations, from those wanting to maintain marijuana’s illegality to advocates seeking its descheduling. Regardless of the DEA’s recommendation, conflicts between state and federal laws will persist, necessitating congressional action in the long-term. Nonetheless, a significant change in marijuana policy appears inevitable and more imminent than ever before.

Industry companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) will probably be waiting with bated breath to see what decision the DEA makes regarding the change in the scheduling of marijuana.

Cresco Labs Inc. (CRLBF), closed Wednesday's trading session at $2.17, even for the day, on 693,999 volume. The average volume for the last 3 months is 1.775M and the stock's 52-week low/high is $1.00/$4.20.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, StockEarnings, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research has found that patients suffering from moderate to severe PTSD may experience a reduction in their symptoms following treatment with MDMA. The study, which was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), published its findings in the “Nature” journal.

Rick Doblin, president and founder of Multidisciplinary Association for Psychedelic Studies (MAPS), believes that MDMA-assisted therapy is on course for approval by the Food and Drug Administration (FDA) in 2024, thanks to the efforts of many therapists, participants and donors.

The study, which involved a randomized, placebo-controlled, double-blinded trial, recruited 104 individuals with PTSD who received either a placebo or MDMA then underwent talk therapy by qualified therapists. The trial determined that MDMA significantly reduced PTSD symptoms in comparison to the placebo. The findings add to growing literature showing that MDMA could be a game-changer, especially for the many patients who gain no benefit from currently prescribed drugs and therapies.

In their report, the researchers stated that MDMA improved therapy by breaking down boundaries that could hinder patients from processing trauma from their past. They also explained that the drug softened responses to fearful and emotionally challenging stimuli while also producing prosocial feelings that possibly improved patients’ ability to benefit from psychotherapy through the reduction of sensations of threat, fear or even negative emotions.

The researchers added that the MDMA therapy wasn’t considerably affected by substance use disorder or risk of hazardous alcohol, severity of illness, dissociative subtype or adverse childhood experiences. In addition, they observed that while suicidal ideation was observed in patients who received MDMA as well as the placebo, MDMA didn’t heighten this risk.

In their conclusion, the researchers added that the common issues observed included transient, mild increases in heart rate and blood pressure. They noted that the therapy was generally well tolerated among the patients with post-traumatic stress disorder involved in the trial.

For the MAPS formulation to be approved federally, its MAPS Public Benefit Corp. subsidiary will have to file an application with the FDA this year. This, the organization noted last week, could mean that the federal agency could award approval as soon as 2024, which would make MDMA therapy more available.

In 2017, the FDA awarded a Breakthrough Therapy designation to MDMA, based on prior trials that were also sponsored by MAPS.  The organization also revealed that findings from 18 of its phase 1 and 2 trials would make up the basis for its New Drug Application.

When MAPS succeeds in getting MDMA approved by the FDA, it will be a big win for the entire psychedelics industry, including startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL), which are also conducting drug-development programs involving psychedelic substances.

Seelos Therapeutics Inc. (SEEL), closed Wednesday's trading session at $0.3051, off by 69.49%, on 55,058,091 volume. The average volume for the last 3 months is 10.864M and the stock's 52-week low/high is $0.2311/$1.66.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, QualityStocks, Schaeffer's, Kiplinger Today, MarketBeat, StocksEarning, StockMarketWatch, TradersPro, StreetInsider, Early Bird, The Street, Trades Of The Day, StockEarnings, Daily Trade Alert, The Online Investor, TraderPower, TopPennyStockMovers, BUYINS.NET, Zacks, Wealth Insider Alert, GreenCarStocks, InvestorsUnderground, Jason Bond, Cabot Wealth,, PoliticsAndMyPortfolio, StockOodles, The Night Owl, Money Wealth Matters, Profitable Trader Authority, Wealth Daily, Stock Beast, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research published by three different institutions indicates that global electric vehicle sales could surpass 60% of total vehicle sales by 2030. With Climate Week NYC fast approaching, three separate research pieces from the EEIST Project, Systems Change Lab and RMI predict a massive surge in EV sales over the rest of the decade.

RMI analysis found that worldwide EV sales are poised to meet or even surpass the most overzealous timelines for achieving net-zero emissions. In partnership with the Bezos Earth Fund, RMI’s research found that EV sales may make up more than two-thirds of the global market share by 2030 thanks to “exponential growth trends.”

With plenty of countries worldwide working to cut their carbon emissions in the past few years, electric vehicles and green-energy infrastructure have seen significant public and private investments. Although the pace has been extremely slow, electric vehicles have begun encroaching on the demand for conventional diesel and petrol-powered cars.

Sales of fossil fuel vehicles peaked in 2017, RMI notes, and more petrol and diesel-powered cars will be scrapped compared to the ones being sold by mid-decade. RMI’s research indicates that overall sales of new internal combustion cars are about to peak and will be in freefall as the decade draws to a close.

In the meantime, the research indicates that EV sales in major markets, such as China, the United States and Northern Europe, will rise by at least six times through the decade and achieve a market share anywhere between 62% to 86% by the year 2030. Compared to current projections which put electric cars at a 40% market share by the end of the decade, the recent analysis is extremely optimistic about the electric vehicle industry’s growth.

RMI also predicts a 50% drop in EV battery costs through the decade from $151 per kWh to around $60 to $90 per kWh, ultimately contributing to a reduction in overall EV production costs and making electric cars as affordable or even more affordable than fossil fuel cars by 2030. According to RMI, the Chinese market will boast 90% electric vehicle sales by the end of the decade, far ahead of most other electric-vehicle markets.

China is currently the largest electric-vehicle market on the globe and has significantly invested in building up local automakers and EV charging infrastructure. Alongside Norway and the Netherlands, China has shown that nations can accelerate their EV adoption rate to achieve climate change goals.

As more motorists switch to electric vehicles, the competition between different automakers, including Workhorse Group Inc. (NASDAQ: WKHS), is likely to get stiffer as these companies work to dominate the industry.

Workhorse Group Inc. (WKHS), closed Wednesday's trading session at $0.515, off by 6.3636%, on 18,645,153 volume. The average volume for the last 3 months is 12.696M and the stock's 52-week low/high is $0.5125/$3.07.

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, The Street, Prfmonline, MarketClub Analysis, Greenbackers, QualityStocks, MarketBeat, Kiplinger Today, Investopedia, OTCPicks, SmallCapVoice, Ceocast News, The Online Investor, INO Market Report, Early Bird, Zacks, HotOTC, CoolPennyStocks, Daily Trade Alert, Trades Of The Day, InsiderTrades, StockEgg, Penny Invest, Stock Stars, Stock Rich, StocksEarning, The Wealth Report, Top Pros' Top Picks, Top Gun, BestOtc, The Stock Psycho, CNBC Breaking News, HotShotStocks, StockEarnings, StockHotTips, BullRally, Wealth Daily, MadPennyStocks, FeedBlitz, Energy and Capital, PennyInvest, Smartmoneytrading, PennyTrader Publisher, Summa Money, StockRich, Profit Confidential, Today's Financial News, CryptoCurrencyWire, Stockpalooza, PennyStockVille, AlphaShark Trading, Cabot Wealth, Pennybuster, BloomMoney, Atomic Trades, Eagle Financial Publications, CRWEWallStreet, Dynamic Wealth Report, Dawn Report, Blaque Capital Stocks, Standout Stocks, wyatt research newsletter, WiseAlerts, wealthmintrplus, Wealth Whisperer, TipRanks, StockMister, Stock Traders Chat, Penny Stock Finder, Stock Analyzer, Early Investing, Round Up the Bulls, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, Louis Navellier, Green Chip Stocks and Stock Fortune Teller reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Japan is planning to provide new avenues for startups to secure fresh capital from venture capital entities using digital assets instead of conventional stock offerings to expand their funding options. According to a recent report by Nikkei, the Japanese government aims to table the proposal in parliament early next year.

With the change, limited partnerships would have access to a wider variety of assets. Venture capital firms usually employ limited partnerships to pool funds with other businesses for startup investments, limiting their risk to the money they invest.

Historically, the Japanese venture capital ecosystem has been regarded as more conservative compared to its more audacious counterparts, such as Silicon Valley. Stringent regulations and a penchant for risk aversion have defined the investment scene in the country. Currently, the purview of limited partnerships in Japan is confined to traditional assets such as security tokens, stock options and shares. The proposed rule change seeks to incorporate other crypto assets into the list, thereby expanding a relatively underdeveloped investment sector within the nation.

Venture capital has become more significant in Japan’s business environment over the past few years, and predictions indicate that it will continue to gain ground in both the capital markets and the public sphere. Pitchbook data show that the average fundraising size increased by more than 390% between 2022 and 2023, from $65 million to $321 million. The move follows the Japanese government’s commitment made late last year to encourage more investment in startups and other areas of the economy to focus its personnel and financial resources.

The government also intends to eliminate constraints on limited partnerships, which previously mandated that more than one-half of their capital be invested domestically. The expectation is that this will create additional investment opportunities, subsequently enhancing profits and increasing capital allocation to domestic startups.

The third-largest economy in the world, Japan is thought to have a more developed and stringent regulatory environment for cryptocurrencies than most of its Asian competitors. Its recent tightening of the rules is considered a response to criticism leveled at the country two years ago for failing to keep up with other countries’ implementation of digital asset regulations.

The country adopted an investor protection bill in June intended to create a legal framework for stablecoins and designate them as assets tied to fiat currencies. In the same month, it also introduced new antimoney-laundering regulations for cryptocurrencies that call for people and businesses to track the provenance of an asset as well as the sender and recipient.

As more countries such as Japan move to enact laws easing the use of cryptos, industry companies such as Coinbase Global Inc. (NASDAQ: COIN) could see interest in their products growing around the world.

Coinbase Global Inc. (COIN), closed Wednesday's trading session at $76.67, off by 1.8687%, on 5,467,101 volume. The average volume for the last 3 months is 52.264M and the stock's 52-week low/high is $31.55/$114.43.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, Trades Of The Day, MarketClub Analysis, MarketBeat, Daily Trade Alert, Kiplinger Today, StocksEarning, The Online Investor, StockEarnings, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, QualityStocks, Stock Up Featured, StreetAuthority Daily, Daily Profit, The Wealth Report, Top Pros' Top Picks, SmallCapVoice,, SeriousTraders, StockMarketWatch, Wall Street Grand, Profit Trends, Early Bird, Money Morning, INO Market Report, Inside Trading, Jim Cramer, CNBC Breaking News, Cannabis Financial Network News, Louis Navellier, BUYINS.NET, StocksToBuyNow, Outsider Club, Trading For Keeps, MarketClub, AllPennyStocks, Beat The Street, Wealth Daily, Cabot Wealth, VectorVest, Trading Concepts, TradersPro, TheTradingReport, Profit Confidential, Stock Gumshoe, Insider Wealth Advice, Investment U, InvestmentHouse, Rick Saddler, Raging Bull All Access, Investors Alley, 24/7 Trader, Money and Markets and Technology Profits Daily reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cannabis Exchange-Traded Funds (ETFs) surged in value in September as positive federal action renewed investor interest in the cannabis industry. Shortly after the U.S. Department of Health and Human Services recommended that the Drug Enforcement Administration (DEA) reclassify cannabis to Schedule III from Schedule I and ease federal marijuana restrictions, marijuana-related ETFs began to soar as investors started investing in the cannabis industry.

America’s state-legal cannabis sector is the fastest-growing sector in the nation, generating billions of dollars in yearly revenue. However, the industry has been consistently handicapped by federal regulation. Federal law still classifies cannabis as a Schedule I drug with no medical application, which has made operating in the state-level industry extremely difficult. Issues like limited access to banking services and federal financial aid are prevalent throughout the industry and have likely prevented investors from investing in the cannabis sector.

For example, the Poseidon Dynamic Cannabis ETF by AdvisorShares went down in August amid declining investor interest in marijuana. The fund’s comanager Morgan Paxhia said at the time that the closure of the fund was partly due to a “dramatic shift in investor sentiment” that has affected the nation’s state-level marijuana industry.

Now that federal lawmakers are flirting with the idea of decriminalizing and possibly legalizing the quasilegal sector at the federal level, investor interest is rising. Last week, AdvisorShares Pure US cannabis (MSOS) was up by 56% and ETFMG Alternative Harvest (MJ) soared by 47% while both the SP 500 and the Dow Jones Industrial Average were up by just around 0.5%,

Matt Bottomley, an analyst from financial services firm Canaccord Genuity, noted that federal headlines often act as catalysts for how certain stocks trade. He observed that recent cannabis-related headlines had a positive effect on cannabis ETFs.

The Biden administration’s recommendation for cannabis reclassification at the federal level also caused the shares of cannabis companies such as Cronos Group, Tilray Brands and Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) to surge. This has been a boon for cannabis equities, which have suffered from a capital crunch in recent years as many investors withdrew from the industry.

Despite extensive legalization at the state level, federal prohibition has consistently been a thorn in the cannabis industry’s side, limiting the sector’s access to financing and preventing it from expanding to broader markets. The prospect of finally legalizing cannabis at the federal level and eliminating the barriers that limit trade in the sector will likely attract more investors to cannabis-related equities.

Canopy Growth Corp. (CGC), closed Wednesday's trading session at $0.872, off by 15.3398%, on 85,274,504 volume. The average volume for the last 3 months is 83,155 and the stock's 52-week low/high is $0.346/$4.77.

The QualityStocks Company Corner

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0).

Sekur Private Data (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0), a leading Swiss-hosted secure and private communications platform, is reporting that new subscriber signups for its Swiss-hosted privacy VPN, SekurVPN, have grown by more than 100% month-over-month. In addition, the company notes that website traffic has increased by 650% in just the last two weeks. The company is projecting exponential growth by 2024. According to the announcement, the company is seeing "a surge in signups for its VPN solution, as cyberattacks become more and more commonplace and digital identity theft is rampant." Based on that, Sekur is forecasting continued growth for its SekurVPN solution; the company anticipates adding enterprise features and other upgrades to the platform, such as IPv6, the next-generation Internet Protocol ("IP") standard. The company is also looking to launch a full-scale campaign for its VPN solution later this year.

"We are very pleased with the surge in SekurVPN signups in the last month," said Sekur Private Data CEO Alain Ghiai in the press release. "Sales have surpassed our expectations by far, and we are now expecting exponential growth for SekurVPN. The results also do not reflect yet the full-scale launch as we have just completed a prelaunch and are testing the waters. We expect this to be a big success once we launch it on social media and digital paid media. Our prime directive is to provide private and secure communications for everyone, and as we are not connected to any Big Tech platform, we offer a truly independent, private and secure means of communications, without any data mining, through our proprietary technology and our secure servers based in Switzerland. We look forward to continuing to offer true data privacy to all individuals and their businesses, and to protect their intellectual property and privacy from data miners and malicious hackers."

To view the full press release, visit

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.


Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Wednesday's trading session at $0.15, up 8.9325%, on 201,620 volume. The average volume for the last 3 months is 982,179 and the stock's 52-week low/high is $0.027/$0.15.

Recent News

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed

Renovaro recently announced a binding, exclusive letter of intent ("LOI") to add GEDI Cube's artificial intelligence ("AI") data mining technology to its fight against such cancers

GEDI Cube is strengthening its platform's potential by joining with the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists

The companies hope to detect pancreatic tumors at early stages when they can be more effectively treated, using predictive modeling to analyze patients' health profiles and potential responsiveness to therapeutic efforts

Pre-clinical biotechnology innovator Renovaro BioSciences (NASDAQ: RENB) is seeking solutions for hard-to-treat cancers and other illnesses through the use of a proprietary cell and gene solution designed to promote immune system response.

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.


Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Wednesday's trading session at $3.39, up 14.9153%, on 482,806 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.15/$.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company's American Depositary Shares ("ADSs"). According to the announcement, each ADS represented four hundred ordinary shares offered at $1.16 per ADS (or ADS equivalent). The announcement noted that SCNI also issued unregistered warrants in a concurrent private placement comprised of up to 1,146,552 ADSs representing ordinary shares. The warrants have an exercise price of $1.16 per ADS and are immediately exercisable for five and one-half years. The registered direct offering resulted in an estimated $1.33 million before deductions and expenses. The company plans to use the net proceeds for general working capital, R&D, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

To view the full press release, visit

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Wednesday's trading session at $0.9999, up 3.0825%, on 18,267 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.91/$11.80.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SOHM Inc. (OTC: SHMN).

U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California

SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc.

ABBIE is a synthetic enzyme technology that includes a DNA binding solution and a DNA integration solution for introducing a functionally edited genome into an "enhanced" cell that could then be introduced into a patient's body to repair the effects of cellular damage

ABBIE is still in the early stages of development, but a principal aim of SOHM's plans for the technology is to develop cells that can help repair damaged tissues in cardiac patients' hearts

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is an innovator in regenerative medicine, nutraceuticals and cosmeceuticals through the development of cost-effective generic drugs for the breadth of major treatment categories.

SOHM Inc. (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California.

The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. SOHM is dedicated to fully complying with all relevant regulatory prerequisites and upholding the most rigorous industry benchmarks, including the guidelines set forth by WHO-CGMP and USFDA.

Achievements and Milestones

SOHM is a recognized generic pharmaceutical manufacturer, with production and marketing of generic drugs covering all major treatment categories. SOHM also markets innovative formulations and packaging for various therapeutic segments, such as cosmeceuticals, nutraceuticals and OTC oral dosage formulations, with operations spanning India, the Philippines, Uganda, the U.S., the UK and the EU.

SOHM successfully launched a unique and innovative Salic-2 face wash, FōHM by SOHM, during the Oscar after party in Hollywood. The innovative Salic-2 offering in translucent gel form is marketed as an acne medication in the U.S. cosmeceutical market.

With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in India.

In 2012, SOHM gained recognition as “the most emerging company in the recent past” at the National Integrated Medical Association Conference. The company’s growth was underscored by its inclusion in the roster of ‘Fastest Growing Public Companies’ according to the Orange County Business Journal.

SOHM Today

SOHM brings all of its expertise and market knowledge toward a new vision. The company continues to develop, manufacture and market generic pharmaceutical drugs for various treatment categories. It offers its products in various dosage forms, including tablets and capsules, creams and topicals, ointments and liquids. The company also provides anti-arthritic/analgesics, dermatological drugs, gastrointestinal and respiratory drugs, biotechnology products, anesthetics, immunosuppressive agents and other various treatments. In addition, it offers a skincare line that includes dry dermatoses, mixed skin infection, acne vulgaris and seborrheic dermatitis products.

SOHM markets its products directly and through partner alliance agreements to drug wholesalers, mass merchandisers, chain drug stores and mail-order pharmacies primarily in the U.S. and has previously done business in the Far East, Africa and Southeast Asia. The company is working with its alliance partner in the African continent and Latin American countries.

SOHM has developed a comprehensive marketing strategy encompassing a diverse range of tactics to promote all products. SOHM uses the power of digital marketing channels, social media campaigns and targeted advertising to significantly enhance awareness and recognition of product offerings.

All distribution networks are strengthened through valuable partnerships. SOHM has gained access to the extensive U.S. market through a strategic alliance with different wholesalers catering to C-stores and retailers. The company has likewise partnered with a distribution firm that holds a remarkable network of more than 4,500 independent pharmacy accounts.

Additionally, a strong partnership with a prominent distribution network in New Jersey enables SOHM to facilitate nationwide distribution to big distribution houses, hospitals and retail chain stores which include but are not limited to Walmart, Publix, Sam’s and many more retail giants, thus extending the company’s market presence.

SOHM Long-Term

A report by Grand View Research estimated the global nutraceuticals market at $291.33 billion in 2022 and forecasts expansion at a compound annual growth rate (CAGR) of 9.4% from 2023 to 2030. The report states primary factors driving the market growth are preventive health care, increasing instances of lifestyle-related disorders, and rising consumer focus on health-promoting diets. Additionally, increasing consumer spending power in high-growth economies is projected to contribute to the growing demand for nutraceutical products.

Grand View valued the global NSAID market at $19.55 billion in 2021 and forecast it would expand to nearly $30 billion by 2030, marking a CAGR of 5.36% for the period. Projected growth is attributed to factors like the rising prevalence of chronic pain across the world, coupled with a growing global geriatric population. In addition, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in treating headaches, migraine, toothaches and menstrual pain is expected to boost market growth.

Fortune Business Insights estimated that the global cosmeceuticals market was worth $54.57 billion in 2022 and projects the market will grow to a value of $96.23 billion by 2029, marking a CAGR of 8.4% during the forecast period. The report credits the projected growth to the prevalence of skin disorders around the world and the inclination of dermatologists to prescribe or recommend these products as compared to other treatments.

SOHM envisions a future where it evolves into a prominent global corporation, expanding its reach across international borders while upholding its fundamental core values. The company aspires to extend its export portfolio to encompass 11 countries, showcasing a robust international presence.

Aiming for financial stability, SOHM is committed to maintaining sufficient working capital to support its growth endeavors. The company’s forward trajectory involves strategic collaborations, mergers with diverse brands and a focused approach to business expansion through vertical integration and a balanced mix of organic and inorganic strategies.

In this pursuit, SOHM is dedicated to establishing its proprietary network of partners within the over the counter (OTC) sector. Furthermore, the company seeks heightened recognition within crucial therapeutic domains, including oncology, HIV, cardiovascular health, diabetes care and skincare-dermatology, solidifying its prominent standing in these pivotal segments.

Management Team

Baron Night is CEO, President, and Director at SOHM Inc. He has over 40 years of experience in various industries with extensive contacts in emerging markets. His leadership and track record are great assets to the company as SOHM continues to strengthen its position and develop large-scale distribution of generic drug lines.

David Aguliar, Ph.D., is the COO of SOHM. He has 22 years of experience in the pharmaceutical industry, including multiple research positions and scientific publications. He has an extensive background in pharmaceutical Chemistry Manufacturing and Controls (CMC), as well as quality assurance experience in preclinical and Investigational New Drug (IND) application filings of allogeneic cell-based therapies. He has a deep understanding of regulatory and clinical pathways, coupled with an extensive scientific and technical background in the fields of pharmaceuticals, biopharmaceuticals and gene editing tools research.

Dr. Krishna Bhat, MD PHD, FACC, has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which was awarded in recognition of his commitment to excellence in the field of Cardiovascular Care through his leadership as an outstanding physician, researcher, and educator. He is also a recipient of the Miles Canada Fellowship Award and the J. Louis Levesque Fellowship Award from Montreal Heart Institute in Montreal, Canada.

Dewey Rushing is a Senior Compliance Remediation and Quality Professional with over 30 years of experience in Quality Assurance and cGMP Compliance for products regulated by the U.S. Food and Drug Administration (FDA). He served as a trained Consumer Safety Investigator at the FDA and Instructor at the Los Angeles District. He has in-depth knowledge in technology transfer of biologics and pharmaceutical products, as well as validation of manufacturing equipment, facility cleaning and critical utility systems maintenance. He has an extensive background in auditing GMP facilities, implementing quality systems and performing gap assessments of manufacturing processes and facilities. He has also directed remediation projects in response to federal compliance audit observations.

Sowmya Jacob, MBA-PGP, possesses over a decade of accomplished and evolving expertise in human resources management, along with manufacturing and operations management. She earned an MBA, complemented by advanced marketing certifications. Demonstrating a track record of achievement, she excels in cultivating collaborative work environments and orchestrating transformative changes that lead to heightened productivity. With adeptness in business analysis, she has occupied senior managerial roles, showcasing her mastery. An engaged participant in professional circles, she maintains active memberships in SPHR and CHRP.

SOHM Inc. (OTC: SHMN), closed Wednesday's trading session at $0.001, up 11.1111%, on 5,990,465 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0005/$0.0018.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

CEO notes that prospecting, mapping and sampling have provided an extensive base of information to support drilling and IP survey

Last month's property-wide mapping and sampling program confirmed a structural connection between two key sections of the property

This month's drilling program will test the extent of the mineralization and study how the systems at Deer Horn and Pond are related

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) has wrapped up a property-wide mapping and sampling program at its Deer Horn property in west-central British Columbia and is preparing to launch a drill program later this month ( Based on data gathered through mapping and sampling programs, drilling at Deer Horn will focus on the Pond zone copper-gold porphyry target, the company stated (

Following a slew of investments in mining facilities and companies, Saudi Arabia has ventured into the critical metals market. Investments in this market are crucial for advancing the development of world-class mining assets. The country's latest deal is valued at $2.6 billion and involves the biggest mining company in Brazil, a move that may cement its place in this billion-dollar market. The deal is a joint venture between Ma'aden, the state mining company and the nation's sovereign wealth fund. It will see Saudi Arabia purchase a 10% stake in the base metals' division of Vale S.A., which has an estimated value of $26 billion. Vale CEO Eduardo Bartolomeo stated that these investments uniquely positioned the company to meet the increasing demand for green metals, which are necessary for the global transition to clean energy, while remaining committed to sustainable mining and strong social and environmental practices. Saudi Arabia's other investments include a power and gas allocation to EV Metals Arabia from the Saudi Arabian Ministry of Energy and the allocation of 127 hectares of land from the Royal Commission at Yanbu. Other extraction companies such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) are also looking to strengthen the supply chains of critical metals in North America. This puts the region on a firm path to self-sufficiency and reduced dependence on China as the years go by.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.



Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.0764, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.071/$0.1765.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

The global customer engagement solutions market is growing exponentially, driven by reduced churn rates and a preference for e-commerce platforms

Larger companies in the industry, like Service Now, Salesforce, and OpenAI, have seen significant revenue and market caps based on their marketing offerings

Electronic Servitor Publication Network's Digital Engagement Engine(TM) offers a unique multi-channel digital engagement experience that allows for targeting the narrowest of niches

Valued at $19.3 billion in 2022, the global customer engagement solutions market is expected to grow at a CAGR of 10.8% through 2027, with a value of $32.2 billion. Factors contributing to this growth are reduced churn rates and the preference for e-commerce platforms ( Larger companies in the industry have seen significant revenue and market caps due to providing clients with customer engagement solutions. Companies like Service Now ($7.2 billion revenue/$111 billion market cap), Salesforce ($31 billion revenue/$204 billion market cap), and OpenAI ($200 million revenue/$30 billion market cap) share the industry landscape with smaller companies that are making waves in the market.

One of those smaller companies is a market-disrupter and making a difference. Electronic Servitor Publication Network (OTCQB: XESP) is a digital engagement company offering a Managed Service that provides unique digital activation and engagement solutions to companies that seek to optimize their growth. The company's Managed Service is powered by a proven, proprietary technology – the Digital Engagement Engine(TM) – which provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action and drive growth.

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.


Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Wednesday's trading session at $0.065, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.16.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, the company behind the GolfLync app – a social network for matching golf games and players, recently announced growth of its platform to surpass 50,000 members across the United States. "The exponential growth is a testament to the platform's ability to bring golfers together, fostering vibrant communities and connections that continue to flourish… The viral scale of GolfLync's growth can be attributed to the genuine enthusiasm and engagement of its members. Tens of thousands of posts, photos, videos, and tee times have been shared, turning GolfLync into a dynamic hub of golfing activity. The ability to have dedicated posts, chats and feeds for individual clubs adds an extra layer of personalization, allowing members to tailor their experiences to their golfing passions," reads a recent article. "Listening to our users and shaping our features around their needs has been the driving force behind GolfLync's remarkable journey. We are thrilled to see our vision come to life as golfers from all corners of the country come together to create thriving golfing communities," Mike Quiel, co-founder of GolfLync, is quoted as saying.

To view the full article, visit

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.


Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News


Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, is among those seeking to fill the incremental gap in the supply of tin. "Eloro Resources has recently carried out a number of metallurgy studies linked to its flagship Iska Iska deposit; recent tests have revealed its key deposit to contain two extensive areas of potential mineralization – split into areas focused around silver-tin and silver-zinc-lead, respectively… The miner may soon affirm its place as an integral member of tin's global supply chain," a recent article reads, discussing Eloro's efforts leading up to the publishing of its inaugural mineral resource estimate ("MRE") at the end of August. "The level of metallurgical and pyrometallurgical work that has been conducted thus far at Iska Iska is exceptionally high for an inaugural MRE but is justifiable due to the significance of this large potentially open pittable tin and polymetallic resource," Mike Hallewell, C.Eng, Eloro's senior strategic metallurgist, was quoted as saying.

To view the full article, visit

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Wednesday's trading session at $1.482, off by 3.6411%, on 36,864 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.47/$3.135.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Nottingham University researchers have devised a novel means of treating brain cancer that could signal a "quantum leap" in brain-tumor treatments moving forward.  A multidisciplinary research team created a new way of targeting and eliminating cancer cells in typically hard-to-treat types of brain tumors that cause cancer cells to essentially self-destruct. This technique involves leveraging bio-nanoantenna, extremely tiny gold particles (nanoparticles) coated with redox active molecules that are specialized to bring about programmed cell death (apoptosis). Upon electrical stimulation, bio-nanoantenna can induce the self-destruction of brain tumor cells, giving physicians a potential treatment option with much higher chances of better health outcomes. Under Nottingham University's School of Pharmacy's leadership, the research team specifically focused on glioblastoma, an extremely hard-to-treat type of brain cancer with an average life expectancy of only 14 to 16 months after diagnosis. Research shows that 6.8% of patients survive for five years after being diagnosed with glioblastoma while only 1% survive for 10 years after diagnosis. Given that many companies, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are also focused on finding better therapeutics for cancers affecting the brain, the future looks brighter because all these efforts are likely to yield improvements in the way these cancers are treated.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.27, off by 1.5504%, on 11,976 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$7.041.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP) is a leading developer of autonomous security robots ("ASRs") and blue light emergency communication systems. The company has announced its 100th Robot Roadshow landing that will take place on Oct. 3, 2023, at Rich Township High School in Richton Park, Illinois.

The announcement reads, "Knightscope's Robot Roadshow (‘Roadshow') was developed and launched during the pandemic, which brought all tradeshows and related gatherings to a grinding halt and hurled marketing executives into survival mode. The Roadshow was built specifically to enable Knightscope's client development team to remotely demonstrate its technologies without risking exposure. It has since proven to be one of the company's greatest marketing and lead generation tools, directly contributing to countless new sales."

There is no charge to participate in or visit the Roadshow. However, available slots fill up quickly. Appointments are recommended and can be made by visiting the following link:

To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Wednesday's trading session at $0.71, off by 7.8042%, on 1,387,957 volume. The average volume for the last 3 months is 4.977M and the stock's 52-week low/high is $0.36/$3.65.

Recent News

Lucy Scientific Discovery Inc. (NASDAQ: LSDI)

The QualityStocks Daily Newsletter would like to spotlight Lucy Scientific Discovery Inc. (NASDAQ: LSDI).

Lucy Scientific Discovery (NASDAQ: LSDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio IBN ( InvestorBrandNetwork ) , a a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, "From Instagram to High Times: Unpacking the Power of Vast User Networks," please visit:

In the business world, one of the cardinal reasons for mergers and acquisitions (M&As) is the potential for synergistic growth. Successful companies usually measure this in terms of revenue streams, market share and product offerings. However, in the age of digital technology and globalization, a significant facet of growth potential is often found a company's core customer base and digital reputation.

Lucy Scientific Discovery is astutely following this road map utilized by hugely successful corporations by uniquely leveraging user bases to rapidly amplify shareholder value. This well-established, albeit counterintuitive, M&A strategy has been utilized by several major companies.

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry.

The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada).

The company’s mission is to make its products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs, including various mental health and addiction disorders. LSDI targets customers that include an increasing number of the leading universities, hospitals and other public, private and government institutions throughout the world that have launched research programs aimed at understanding the therapeutic potential of a range of psychedelic substances.

The company is headquartered in Victoria, British Columbia, Canada.


LSDI produces a variety of high-quality natural, synthetic and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market. The company believes the emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness. LSDI is dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.

In Canada, the psychedelic compounds that LSDI is approved to produce under its Dealer’s License are regulated under the Controlled Drugs and Substances Act, or CDSA. Those compounds include:

  • Psilocybin
  • Psilocin
  • Lysergic acid diethylamide, or LSD
  • N,N-Dimethyltryptamine, or N,N-DMT
  • 3,4-Methylenedioxymethamphetamine, or MDMA
  • 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B

The company also sells its consumer psychotropic products directly online and through retailers. Those products, described as microdose mushroom formulations, include a sleep aid, Twilight, and a mindfulness enhancer, Mindful.

Market Opportunity

According to a report from Global Market Insights, the psychotropics drug market had an estimated value of $20.2 billion in 2022 and is projected to reach a value of nearly $37.6 billion by 2032. That represents a CAGR of 6.4% for the forecast period. Factors driving market growth include the increasing prevalence of mental disorders, technological advancements in drug development, a rising geriatric population and increasing healthcare expenditures, the report states.

A growing awareness of mental health issues and an effort to reduce the stigma surrounding psychiatric disorders have encouraged more individuals to seek help, which in turn boosts the market. In addition, advancements in neuroscience, pharmacology and drug development have led to the discovery of new and more effective central nervous system therapeutics.

Innovative treatments offering better outcomes with fewer side effects attract patients and healthcare providers, also driving market growth.

Management Team

LSDI’s executive team brings deep experience in the development and commercialization of products featuring controlled substances, as well as the navigation of regulatory structures applicable to these products.

Richard Nanula is Chairman and CEO of LSDI. He has more than 35 years of leadership experience at several of the largest companies in the world, having been a senior executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. He has also served as a board member for Boeing Corporation and Starwood Capital, where he provided corporate guidance and oversight. He holds an MBA from Harvard Business School.

Assad J. Kazeminy, Ph.D., is Chief Scientific Officer at LSDI. He previously served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, and he has founded several drug development companies. He has over 30 years of research and development experience in the biopharmaceutical industry. He received his Ph.D. in Pharmaceutical Science and Biochemistry from Esfahan University in Iran. He completed a Post Doctorate course of study at the University of Southern California Medical School, Department of Pharmacology.

Brian Zasitko, CPA, CA, is the company’s CFO. He is a Director of Invictus Accounting Group LLP, a professional services firm providing finance, advisory and accounting services. He also serves as CFO of Lobe Sciences Ltd., a company developing psychedelic compounds as therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. He has an undergraduate degree from Simon Fraser University and a CPA (CA) from Certified Professional Accountants, British Columbia.

Lucy Scientific Discovery Inc. (NASDAQ: LSDI), closed Wednesday's trading session at $0.65, off by 0.15361%, on 80,370 volume. The average volume for the last 3 months is 118,984 and the stock's 52-week low/high is $0.55/$4.00.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Four decades after the Orphan Drug Act was passed, hundreds of ‘orphan' drugs have been approved for use

Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation

With recent ODD and FTD designations, Genprex is on the verge of commencing patient treatment in small cell lung cancer in Q4 2023

NetworkNewsWire Editorial Coverage: More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation ("ODD") to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer ("SCLC"). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY)Jazz Pharmaceuticals PLC (NASDAQ: JAZZ)ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. "Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh. Genprex is developing technologies to administer disease-fighting genes that will provide new therapies in the fight against cancer and diabetes for large patient populations. In regard to the company's diabetes approach, the Pdx1 and MafA genes are delivered directly to the pancreas through a novel infusion process (gene therapy candidates ‘GPX-002' and ‘GPX-003')," a recent article reads. "We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program," Genprex chairman, president and CEO Rodney Varner is quoted as saying. "The addition of this license to MafB promoter technology expands and strengthens the potential for this novel gene therapy to treat type 1 and type 2 diabetes."

To view the full article, visit

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $0.448, off by 0.994475%, on 128,566 volume. The average volume for the last 3 months is 716,273 and the stock's 52-week low/high is $0.425/$1.94.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.